首页/数据集/Selective Loss of RB in Resistant EGFR Mutant Lung Adenocarcinomas that Transform to SCLC. Selective Loss of RB in Resistant EGFR Mutant Lung Adenocarcinomas that Transform to SCLC

Selective Loss of RB in Resistant EGFR Mutant Lung Adenocarcinomas that Transform to SCLC. Selective Loss of RB in Resistant EGFR Mutant Lung Adenocarcinomas that Transform to SCLC

NIAID Data Ecosystem2026-03-07 收录

肿瘤耐药机制

肿瘤谱系转化

数据链接：

https://www.ncbi.nlm.nih.gov/bioproject/PRJNA271815 数据链接链接失效反馈

官方服务：

资源简介：

This SuperSeries is composed of the SubSeries listed below. Overall design: Refer to individual Series

应用场景：

创建时间：

2015-01-07

肿瘤耐药机制

组合治疗

EGFR-mut NSCLC lines show differential suceptibility to inhibition of tankyrase in the presence of EGFR inhibitors Overall design: NSCLC cells were treated in quadruplicate with gefitinib, AZ1366 (tan

NIAID Data Ecosystem80

Ploidy variations between secondary resistant and parental soft-tissue sarcoma cell lines.

肿瘤耐药机制

细胞倍性分析

only sensitive cloneonly resistant clone-: absence of allelic imbalancePloidy variations between secondary resistant and parental soft-tissue sarcoma cell lines.

Figshare2015-12-03 更新50

Novel Indole–Chalcone Derivative-Ligated Platinum(IV) Prodrugs Attenuate Cisplatin Resistance in Lung Cancer through ROS/ER Stress and Mitochondrial Dysfunction

肿瘤耐药机制

特定类别药物开发

Developing multifunctional platinum(IV) prodrugs via integrating bioactive pharmacophores into one entity is an attractive strategy to ameliorate the defects of platinum(II) drugs. Herein, a series

NIAID Data Ecosystem40

Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway

肿瘤耐药机制

信号通路靶向治疗

BackgroundThe sustained clinical activity of the BRAF inhibitor vemurafenib (PLX4032/RG7204) in patients with BRAFV600 mutant melanoma is limited primarily by the development of acquired resistance le

Figshare2016-01-18 更新50

Suppression of adaptive responses to targeted cancer therapy by transcriptional repression [RNA-seq]. Homo sapiens

肿瘤耐药机制

转录组药物响应

Large-scale genomic profiling efforts have facilitated the characterization of molecular alterations in cancers and aided the development of targeted kinase inhibitors for a wide array of cancer types

NIAID Data Ecosystem50

Selective Loss of RB in Resistant EGFR Mutant Lung Adenocarcinomas that Transform to SCLC. Selective Loss of RB in Resistant EGFR Mutant Lung Adenocarcinomas that Transform to SCLC

资源简介：

相关数据集